MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:41Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Alpha-2 agonists]]
			[[Category:Glaucoma medications]]
			[[Category:Ocular hypotensive agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #213

2026-05-23T04:08:53Z

parser-claude batch MedTemplate pre-fill, Top 300 #213

New page

{{MedTemplate
| generic = Brimonidine
| brand = Alphagan P (ophthalmic glaucoma), Mirvaso (topical rosacea)
| structure =
| classes = [[:Category:Alpha-2_agonists|Alpha-2 adrenergic agonist]], [[:Category:Glaucoma_medications|Glaucoma medication]], [[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]]
| uses = <vote slug="primary-open-angle-glaucoma-use">Primary open-angle glaucoma</vote>, <vote slug="ocular-hypertension-use">Ocular hypertension</vote>, <vote slug="rosacea-erythema-use">Persistent erythema of rosacea (topical Mirvaso)</vote>
| starting_dose = Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily
| preparations = 0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza)
| fda_max = TID per eye
| pill_id =
| routes = Topical ophthalmic, topical skin
| onset = IOP lowering at 1 hour; max at 2-3 hours
| duration = 8-12 hours
| halflife = ~3 hours<ref name="alphagan-label">FDA Prescribing Information, Alphagan P (brimonidine tartrate), Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021262s020lbl.pdf</ref>
| bioavailability = Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children<ref name="alphagan-label" />
| pregnancy = Limited data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="brimonidine-mech-claim">Brimonidine is a selective α2 adrenergic receptor agonist; in the ciliary body it reduces aqueous humor production and increases uveoscleral outflow, lowering intraocular pressure by ~20-25%.</vote> Systemic absorption with α2-mediated CNS depression (somnolence, fatigue) limits dosing in children and can be clinically significant in adults using bilateral ophthalmic therapy. Allergic conjunctivitis (delayed-onset, after months of use) is a recognized class effect. The topical rosacea formulation exploits cutaneous α-mediated vasoconstriction for transient erythema reduction<ref name="alphagan-label" />.
}}

== References ==
<references />

Brimonidine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #213